Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

Journal of Experimental Medicine

Volumn 209, Issue 2, 2012, Pages 259-273

  Weigert, Oliver ^a   Lane, Andrew A ^a   Bird, Liat ^a   Kopp, Nadja ^a   Chapuy, Bjoern ^a   van Bodegom, Diederik ^a   Toms, Angela V ^a,d   Marubayashi, Sachie ^b   Christie, Amanda L ^a   McKeown, Michael ^a   Paranal, Ronald M ^a   Bradner, James E ^a   Yoda, Akinori ^a   Gaul, Christoph ^c   Vangrevelinghe, Eric ^c   Romanet, Vincent ^c   Murakami, Masato ^c   Tiedt, Ralph ^c   Ebel, Nicolas ^c   Evrot, Emeline ^c   De Pover, Alain ^c   Régnier, Catherine H ^c   Erdmann, Dirk ^c   Hofmann, Francesco ^c   Eck, Michael J ^a,d   Sallan, Stephen E ^a   Levine, Ross L ^b   Kung, Andrew L ^a,d   Baffert, Fabienne ^c   Radimerski, Thomas ^c   Weinstock, David M ^a,d   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; ANTINEOPLASTIC AGENT; BVB 808; CYTOKINE RECEPTOR; CYTOKINE RECEPTOR LIKE FACTOR 2; HEAT SHOCK PROTEIN 90 INHIBITOR; HEAT SHOCK TRANSCRIPTION FACTOR 1; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; BONE MARROW; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; GENE REARRANGEMENT; GENETIC RESISTANCE; HEMATOCRIT; HEMATOPOIESIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLEEN WEIGHT;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA PRIMERS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; ISOXAZOLES; JANUS KINASE 2; LEUKEMIA, B-CELL; LUCIFERASES; MICE; MICE, INBRED BALB C; MUTAGENESIS; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; PHOSPHORYLATION; RECEPTORS, CYTOKINE; RESORCINOLS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; X-RAY MICROTOMOGRAPHY;

EID: 84856932936     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20111694     Document Type: Article

References (55)

1. Abramson, J.S., W. Chen, P. Juszczynski, H. Takahashi, D. Neuberg, J.L. Kutok, K. Takeyama, and M.A. Shipp. 2009. The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas. Br. J. Haematol. 144:358-366. http://dx.doi.org/10.1111/j.1365-2141.2008.07484.x
2. Azam, M., R.R. Latek, and G.Q. Daley. 2003. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 112:831-843. http://dx.doi.org/10.1016/S0092-8674(03)00190-9
3. Baffert, F., C.H. Régnier, A. De Pover, C. Pissot-Soldermann, G.A. Tavares, F. Blasco, J. Brueggen, P. Chène, P. Drueckes, D. Erdmann, et al. 2010. Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. Mol. Cancer Ther. 9:1945-1955. http://dx.doi.org/10.1158/1535-7163.MCT-10-0053
4. Bareng, J., I. Jilani, M. Gorre, H. Kantarjian, F. Giles, A. Hannah, and M. Albitar. 2007. A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry. Leuk. Lymphoma. 48:2189-2195. http://dx.doi.org/10.1080/10428190701607576
5. Cerchietti, L.C., E.C. Lopes, S.N. Yang, K. Hatzi, K.L. Bunting, L.A. Tsikitas, A. Mallik, A.I. Robles, J. Walling, L. Varticovski, et al. 2009. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat. Med. 15:1369-1376. http://dx.doi.org/10.1038/nm.2059
6. Chou, T.C., and P. Talalay. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55. http://dx.doi.org/10.1016/0065-2571(84)90007-4
7. Druker, B.J., C.L. Sawyers, H. Kantarjian, D.J. Resta, S.F. Reese, J.M. Ford, R. Capdeville, and M. Talpaz. 2001. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344:1038-1042. http://dx.doi.org/10 .1056/NEJM200104053441402
8. Eccles, S.A., A. Massey, F.I. Raynaud, S.Y. Sharp, G. Box, M. Valenti, L. Patterson, A. de Haven Brandon, S. Gowan, F. Boxall, et al. 2008. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 68:2850-2860. http://dx.doi.org/10.1158/0008-5472.CAN-07-5256
9. Engelman, J.A., and J. Settleman. 2008. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr. Opin. Genet. Dev. 18:73-79. http:// dx.doi.org/10.1016/j.gde.2008.01.004
10. Flaherty, K.T., I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, J.A. Sosman, P.J. O'Dwyer, R.J. Lee, J.F. Grippo, K. Nolop, and P.B. Chapman. 2010. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363:809-819. http://dx.doi.org/10.1056/NEJMoa1002011
11. Grandage, V.L., T. Everington, D.C. Linch, and A. Khwaja. 2006. Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells. Br. J. Haematol. 135:303-316. http://dx.doi.org/10.1111/j.1365-2141.2006.06291.x
12. Green, M.R., S. Monti, S.J. Rodig, P. Juszczynski, T. Currie, E. O'Donnell, B. Chapuy, K. Takeyama, D. Neuberg, T.R. Golub, et al. 2010. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 116:3268-3277. http://dx.doi.org/10.1182/blood-2010-05-282780
13. Griswold, I.J., M. MacPartlin, T. Bumm, V.L. Goss, T. O'Hare, K.A. Lee, A.S. Corbin, E.P. Stoffregen, C. Smith, K. Johnson, et al. 2006. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol. Cell. Biol. 26:6082-6093. http://dx.doi.org/10.1128/MCB.02202-05
14. Haan, S., S. Wüller, J. Kaczor, C. Rolvering, T. Nöcker, I. Behrmann, and C. Haan. 2009. SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling. Oncogene. 28:3069-3080. http://dx.doi.org/10.1038/onc.2009.155
15. Hart, S., K.C. Goh, V. Novotny-Diermayr, C.Y. Hu, H. Hentze, Y.C. Tan, B. Madan, C. Amalini, Y.K. Loh, L.C. Ong, A.D. William, A. Lee, A. Poulsen, R. Jayaraman, K.H. Ong, K. Ethirajulu, B.W. Dymock, and J.W. Wood. 2011. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia
16. Harvey, R.C., C.G. Mullighan, I.M. Chen, W. Wharton, F.M. Mikhail, A.J. Carroll, H. Kang, W. Liu, K.K. Dobbin, M.A. Smith, et al. 2010. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood. 115:5312- 5321. http://dx.doi.org/10.1182/blood-2009-09-245944
17. Hertzberg, L., E. Vendramini, I. Ganmore, G. Cazzaniga, M. Schmitz, J. Chalker, R. Shiloh, I. Iacobucci, C. Shochat, S. Zeligson, et al. 2010. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood. 115:1006-1017. http://dx.doi.org/10.1182/blood-2009-08-235408
18. Ihle, J.N., and D.G. Gilliland. 2007. Jak2: normal function and role in hematopoietic disorders. Curr. Opin. Genet. Dev. 17:8-14. http://dx.doi.org/10.1016/j.gde.2006.12.009
19. James, C., V. Ugo, J.P. Le Couédic, J. Staerk, F. Delhommeau, C. Lacout, L. Garçon, H. Raslova, R. Berger, A. Bennaceur-Griscelli, et al. 2005. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 434:1144-1148. http://dx.doi.org/10.1038/nature03546
20. Jensen, M.R., J. Schoepfer, T. Radimerski, A. Massey, C.T. Guy, J. Brueggen, C. Quadt, A. Buckler, R. Cozens, M.J. Drysdale, et al. 2008. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res. 10:R33. http://dx.doi.org/10.1186/bcr1996
21. Joensuu, H., P.J. Roberts, M. Sarlomo-Rikala, L.C. Andersson, P. Tervahartiala, D. Tuveson, S. Silberman, R. Capdeville, S. Dimitrijevic, B. Druker, and G.D. Demetri. 2001. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344:1052-1056. http://dx.doi.org/10.1056/NEJM200104053441404
22. Kiss, R., P.P. Sayeski, and G.M. Keserũ. 2010. Recent developments on JAK2 inhibitors: a patent review. Expert Opin Ther Pat. 20:471-495. http://dx.doi.org/10.1517/13543771003639436
23. Levine, R.L., M. Wadleigh, J. Cools, B.L. Ebert, G. Wernig, B.J. Huntly, T.J. Boggon, I. Wlodarska, J.J. Clark, S. Moore, et al. 2005. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 7:387-397. http://dx.doi.org/10.1016/j.ccr.2005.03.023
24. Levine, R.L., A. Pardanani, A. Tefferi, and D.G. Gilliland. 2007. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat. Rev. Cancer. 7:673-683. http://dx.doi.org/10.1038/nrc2210
25. Levy, D.S., J.A. Kahana, and R. Kumar. 2009. AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood. 113:1723-1729. http://dx.doi.org/10.1182/blood-2008-02-137737
26. Lucet, I.S., E. Fantino, M. Styles, R. Bamert, O. Patel, S.E. Broughton, M. Walter, C.J. Burns, H. Treutlein, A.F. Wilks, and J. Rossjohn. 2006. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood. 107:176-183. http://dx.doi.org/10.1182/blood-2005-06-2413
27. Manshouri, T., A. Quintás-Cardama, R.H. Nussenzveig, A. Gaikwad, Z. Estrov, J. Prchal, J.E. Cortes, H.M. Kantarjian, and S. Verstovsek. 2008. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci. 99:1265-1273. http://dx.doi.org/10.1111/j.1349-7006.2008.00817.x
28. - stem cell-like breast cancer cells in human tumors. J. Clin. Invest. 121:2723-2735. http://dx.doi.org/10.1172/JCI44745
29. Marubayashi, S., P. Koppikar, T. Taldone, O. Abdel-Wahab, N. West, N. Bhagwat, E. Caldas-Lopes, K.N. Ross, M. Gönen, A. Gozman, et al. 2010. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J. Clin. Invest. 120:3578-3593. http://dx.doi.org/10.1172/JCI42442
30. Mullighan, C.G., J.R. Collins-Underwood, L.A. Phillips, M.G. Loudin, W. Liu, J. Zhang, J. Ma, E. Coustan-Smith, R.C. Harvey, C.L. Willman, et al. 2009a. Rearrangement of CRLF2 in B-progenitor- and Down syndromeassociated acute lymphoblastic leukemia. Nat. Genet. 41:1243-1246. http://dx.doi.org/10.1038/ng.469
31. Mullighan, C.G., J. Zhang, R.C. Harvey, J.R. Collins-Underwood, B.A. Schulman, L.A. Phillips, S.K. Tasian, M.L. Loh, X. Su, W. Liu, et al. 2009b. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA. 106:9414-9418. http://dx.doi.org/10.1073/pnas.0811761106
32. Najfeld, V., A. Cozza, W. Berkofsy-Fessler, J. Prchal, and A. Scalise. 2007. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Phnegative MPD, myelodysplasia, and B-lymphoid neoplasms. Exp. Hematol. 35:1668-1676. http://dx.doi.org/10.1016/j.exphem.2007.08.025
33. Neckers, L. 2007. Heat shock protein 90: the cancer chaperone. J. Biosci. 32:517-530. http://dx.doi.org/10.1007/s12038-007-0051-y
34. Pardanani, A. 2008. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia. 22:23- 30. http://dx.doi.org/10.1038/sj.leu.2404948
35. Pardanani, A., J.R. Gotlib, C. Jamieson, J.E. Cortes, M. Talpaz, R.M. Stone, M.H. Silverman, D.G. Gilliland, J. Shorr, and A. Tefferi. 2011. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J. Clin. Oncol. 29:789-796. http://dx.doi.org/10.1200/JCO.2010.32.8021
36. Pikman, Y., B.H. Lee, T. Mercher, E. McDowell, B.L. Ebert, M. Gozo, A. Cuker, G. Wernig, S. Moore, I. Galinsky, et al. 2006. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 3:e270. http://dx.doi.org/10.1371/journal.pmed.0030270
37. Proia, D.A., K.P. Foley, T. Korbut, J. Sang, D. Smith, R.C. Bates, Y. Liu, A.F. Rosenberg, D. Zhou, K. Koya, et al. 2011. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS ONE. 6:e18552. http://dx.doi.org/10.1371/journal.pone.0018552
38. Reich, M., T. Liefeld, J. Gould, J. Lerner, P. Tamayo, and J.P. Mesirov. 2006. GenePattern 2.0. Nat. Genet. 38:500-501. http://dx.doi.org/10.1038/ng0506-500
39. Richardson, P.G., C.S. Mitsiades, J.P. Laubach, S. Lonial, A.A. Chanan-Khan, and K.C. Anderson. 2011. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br. J. Haematol. 152:367-379. http://dx.doi.org/10.1111/j.1365-2141.2010.08360.x
40. Rui, L., N.C. Emre, M.J. Kruhlak, H.J. Chung, C. Steidl, G. Slack, G.W. Wright, G. Lenz, V.N. Ngo, A.L. Shaffer, et al. 2010. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell. 18:590-605. http://dx.doi.org/10.1016/j.ccr.2010.11.013
41. Russell, L.J., M. Capasso, I. Vater, T. Akasaka, O.A. Bernard, M.J. Calasanz, T. Chandrasekaran, E. Chapiro, S. Gesk, M. Griffiths, et al. 2009. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood. 114:2688-2698. http://dx.doi.org/10.1182/blood-2009-03-208397
42. Sanda, T., X. Li, A. Gutierrez, Y. Ahn, D.S. Neuberg, J. O'Neil, P.R. Strack, C.G. Winter, S.S. Winter, R.S. Larson, et al. 2010. Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia. Blood. 115:1735-1745. http://dx.doi.org/10.1182/blood-2009-07-235143
43. Shochat, C., N. Tal, O.R. Bandapalli, C. Palmi, I. Ganmore, G. te Kronnie, G. Cario, G. Cazzaniga, A.E. Kulozik, M. Stanulla, et al. 2011. Gain-of-function mutations in interleukin-7 receptor-? (IL7R) in childhood acute lymphoblastic leukemias. J. Exp. Med. 208:901-908. http://dx.doi.org/10.1084/jem.20110580
44. Soverini, S., A. Hochhaus, F.E. Nicolini, F. Gruber, T. Lange, G. Saglio, F. Pane, M.C. Muller, T. Ernst, G. Rosti, K. Porkka, M. Baccarani, N.C. Cross, and G. Martinelli. 2011. Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood
45. Stühmer, T., A. Zöllinger, D. Siegmund, M. Chatterjee, E. Grella, S. Knop, M. Kortüm, C. Unzicker, M.R. Jensen, C. Quadt, et al. 2008. Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia. 22:1604-1612. http://dx.doi.org/10.1038/leu.2008.111
46. Subramanian, A., P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette, A. Paulovich, S.L. Pomeroy, T.R. Golub, E.S. Lander, and J.P. Mesirov. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA. 102:15545-15550. http://dx.doi.org/10.1073/pnas.0506580102
47. Trepel, J., M. Mollapour, G. Giaccone, and L. Neckers. 2010. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer. 10:537-549. http://dx.doi.org/10.1038/nrc2887
48. Verstovsek, S. 2009. Therapeutic potential of JAK2 inhibitors. Hematology Am. Soc. Hematol. Educ. Program 2009:636-642.
49. Verstovsek, S., H. Kantarjian, R.A. Mesa, A.D. Pardanani, J. Cortes-Franco, D.A. Thomas, Z. Estrov, J.S. Fridman, E.C. Bradley, S. Erickson-Viitanen, K. Vaddi, R. Levy, and A. Tefferi. 2011. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 363:1117-1127. http://dx.doi.org/10.1056/NEJMoa1002028
50. Wang, Y., W. Fiskus, D.G. Chong, K.M. Buckley, K. Natarajan, R. Rao, A. Joshi, R. Balusu, S. Koul, J. Chen, et al. 2009. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood. 114:5024-5033. http://dx.doi.org/10.1182/blood-2009-05-222133
51. Wardrop, D., and D.P. Steensma. 2009. Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category? Br. J. Haematol. 144:809-817. http://dx.doi.org/10.1111/j.1365-2141.2008.07526.x
52. Weisberg, E., A.L. Kung, R.D. Wright, D. Moreno, L. Catley, A. Ray, L. Zawel, M. Tran, J. Cools, G. Gilliland, et al. 2007. Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Mol. Cancer Ther. 6:1951-1961. http://dx.doi.org/10.1158/1535-7163.MCT-06-0810
53. Wernig, G., M.G. Kharas, R. Okabe, S.A. Moore, D.S. Leeman, D.E. Cullen, M. Gozo, E.P. McDowell, R.L. Levine, J. Doukas, et al. 2008. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 13:311-320. http://dx.doi.org/10.1016/j.ccr.2008.02.009
54. Yoda, A., Y. Yoda, S. Chiaretti, M. Bar-Natan, K. Mani, S.J. Rodig, N. West, Y. Xiao, J.R. Brown, C. Mitsiades, et al. 2010. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA. 107:252-257. http://dx.doi.org/10.1073/pnas.0911726107
55. Zhou, W., W. Hur, U. McDermott, A. Dutt, W. Xian, S.B. Ficarro, J. Zhang, S.V. Sharma, J. Brugge, M. Meyerson, et al. 2010. A structure-guided approach to creating covalent FGFR inhibitors. Chem. Biol. 17:285-295. http://dx.doi.org/10.1016/j.chembiol.2010.02.007